NCT07016867

Brief Summary

A varicocele is defined as an abnormal venous dilatation and/or tortuosity of the pampiniform plexus in the scrotum. Although varicoceles are almost always and more common on the left side, up to 50% of the men with varicocele, have bilateral varicoceles. Varicocele has a negative impact on spermatogenesis, testicular volume, Standard semen parameters, and fertilization, implantation, and embryo outcomes.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
126

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2024

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

May 28, 2025

Completed
15 days until next milestone

First Posted

Study publicly available on registry

June 12, 2025

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 20, 2025

Completed
11 days until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2025

Completed
Last Updated

June 12, 2025

Status Verified

September 1, 2024

Enrollment Period

12 months

First QC Date

May 28, 2025

Last Update Submit

June 11, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of participants with Treatment of Teratozoospermia

    Treatment of the male patients that suffering from abnormally shaped sperms (Teratozoospermia) by medical treatment and or subinguinal varicocelcetomy

    3 months

Study Arms (3)

Group of l-carnitine and antioxidant

ACTIVE COMPARATOR

About 42 male patients suffering from teratozoospermia will take medical treatment (l-carnitine and antioxidant) once daily for 3 months

Drug: l-carnitine

Group of varicocelectomy

ACTIVE COMPARATOR

About 42 male patients suffering from teratozoospermia will undergo subinguinal varicocelectomy.

Drug: l-carnitine

Group of Mixed Treatment(varicocelectomy then l-carnitine and antioxidant)

ACTIVE COMPARATOR

About 42 male patients suffering from teratozoospermia will undergo subinguinal varicocelectomy then adjuvant treatment (l-carnitine and antioxidant) for 3 months.

Drug: l-carnitine

Interventions

to compare the efficacy of medical treatment (l-carnitine and antioxidants) versus surgical treatment (varicocelectomy) versus surgical treatment and medical treatment (varicocelectomy with adjuvant medications) on pregnancy rate on varicocele related subfertility patients with isolated teratozoospermia.

Also known as: Antioxidants, varicocelectomy
Group of Mixed Treatment(varicocelectomy then l-carnitine and antioxidant)Group of l-carnitine and antioxidantGroup of varicocelectomy

Eligibility Criteria

Age20 Years - 50 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Sub-fertile men with clinically palpable varicoceles ( unilateral or bilateral ).
  • Men with teratozoospermia.

You may not qualify if:

  • Recurrent varicoceles.
  • Significant medical diseases as: Hepatic insufficiency.
  • Hypersensitivity to the drugs.
  • Female factor of infertility.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

South Valley University Hospital

Qina, South Valley, Egypt

RECRUITING

MeSH Terms

Conditions

Teratozoospermia

Interventions

CarnitineAntioxidants

Condition Hierarchy (Ancestors)

Infertility, MaleGenital Diseases, MaleGenital DiseasesUrogenital DiseasesInfertilityMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

Trimethyl Ammonium CompoundsQuaternary Ammonium CompoundsAminesOrganic ChemicalsBiological FactorsMolecular Mechanisms of Pharmacological ActionPharmacologic ActionsChemical Actions and UsesProtective AgentsPhysiological Effects of DrugsSpecialty Uses of Chemicals

Study Officials

  • Mohammad Sayed Abdel-Kader, Professor

    Urology Department, Faculty of Medicine, South Valley University, Qena, Egypt

    STUDY CHAIR

Central Study Contacts

Marwan Mohamed Ali Bastawy, Resident

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident of Urology, Faculty of Medicine

Study Record Dates

First Submitted

May 28, 2025

First Posted

June 12, 2025

Study Start

September 1, 2024

Primary Completion

August 20, 2025

Study Completion

August 31, 2025

Last Updated

June 12, 2025

Record last verified: 2024-09

Locations